George D. Yancopoulos, MD, PhD

President of Regeneron Laboratories & Chief Scientific Officer
Regeneron Pharmaceuticals
Tarrytown, NY

Dr. Yancopoulos graduated as valedictorian of both the Bronx High School of Science and Columbia College, and then earned his MD & PhD degrees at Columbia University’s College of Physicians and Surgeons. Dr. Yancopoulos left academia in 1989 to become scientific founder of Regeneron Pharmaceuticals, where he is President of Regeneron Laboratories and Chief Scientific Officer.

Dr. Yancopoulos is a rare individual who has not only built one of the world’s “top ten” biotech companies from the ground up (working together with his long-time friend and partner, Dr. Len Schleifer, who is CEO of Regeneron), but simultaneously been recognized as a world-class basic science researcher, while also inventing some of the most valuable technologies and FDA-approved drugs in the industry.

Dr. Yancopoulos has authored more than 350 scientific manuscripts, and, according to a study by the Institute for Scientific Information, was the eleventh most highly cited scientist in the world during the 1990′s. In 2004, he was elected to both the National Academy of Sciences and the American Academy of Sciences.

Working with his team at Regeneron, Dr. Yancopoulos holds almost 100 patents, including for Regeneron’s foundational platforms for target and drug discovery such as Trap Technology, VelociGene® (which was utilized by the NIH for its $50M “Knock-Out the Mouse Genome Project”) and VelocImmuneTM (which is arguably one of the most valuable biotechnologies ever invented, having already generated more than $2.5B in licensing and collaboration revenues).

Dr. Yancopoulos is also a principal inventor and developer of Regeneron’s three FDA-approved drugs, including EYLEA® (VEGF Trap-Eye, a new treatment for age-related macular degeneration), ZALTRAP® (VEGF Trap-Onc, for colorectal cancer), and ARCALYST® (the IL1-Trap, for orphan inflammatory disease).  EYLEA® has already achieved blockbuster status, with one of the largest first-full year launches in biotech history.

Dr. Yancopoulos’ team has recently progressed several fully human monoclonal antibodies (derived using his VelocImmuneTM platform) into advanced human trials for various indications, including cholesterol-lowering, rheumatoid arthritis, allergic asthma and atopic dermatitis.